Navigation Links
Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
Date:1/9/2012

in basic research. Optimer will, however, retain its clinical R&D capabilities to develop product candidates.

Hospital Formulary and Patient Access Update
At the end of 2011 DIFICID was on formulary at more than 450 hospitals, a 30% increase in formulary adoption since mid November. Optimer continues to make progress in formulary adoption by hospitals.

Patient access to DIFICID has also improved. Currently:

  • DIFICID is covered by 89% of Optimer's targeted payor plans, meaning approximately 75% of all covered lives in the United States have access to DIFICID
  • 90% of targeted commercial payors and 82% of targeted Medicare Part D payors cover DIFICID 
  • The top five commercial Pharmacy Benefit Managers (PBMs) and four of the top five Medicare PBMs cover DIFICID
  • Commercial and Medicare Part D DIFICID copayment amounts are comparable to Vancocin

Important Safety Information for DIFICID
DIFICID should not be used for systemic infections. Only use DIFICID for infection proven or strongly suspected to be caused by C. difficile. Prescribing DIFICID in the absence of a proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria. The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%)

Please visit www.DIFICID.com or call 855-DIFICID (343-4243) for full prescribing information for DIFICID.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commerci
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
4. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
5. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
6. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
7. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
8. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
10. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
11. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), an ... services for the lawfully organized cannabis industry, is ... the Company,s name and symbol change request. Effective ... known as Chuma Holdings, Inc. ... with the Company,s wholly-owned subsidiary, Chuma Holdings, Inc., ...
(Date:8/29/2014)... 29, 2014  A Boston Scientific Corporation (NYSE: ... stent removability and preliminary long term stricture resolution ... the August issue of the peer-reviewed journal, Gastroenterology. ... is being conducted in 11 countries and five ... metal stents (FCSEMS) after extended indwell (i.e., up ...
(Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Benefiting ... for medical expenses, the Chinese orthopedic instrument market demand ... CAGR of 19.2% during 2009-2013. Trauma products, spine products ... instruments in China , of which ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2
... - Inovio Biomedical,Corporation (AMEX:INO), focused on the ... diseases and a novel alternative to,surgery to ... partner, Vical Incorporated, presented positive interim,safety and ... ongoing Phase I,clinical trial using Inovio's electroporation ...
... Clinical results from a,Phase II study presented ... Society (AHS) annual meeting showed that MK-0974, ... significantly improved migraine pain relief,two hours after ... was,sustained through 24 hours. MK-0974 was generally ...
Cached Medicine Technology:Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 2Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 3Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 4Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 5Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5
(Date:8/30/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Cell ... The report then explores global and China’s top ... capacity, Production value, and market share etc. The ...
(Date:8/30/2014)... 2014 Insomnia causes disturbances in every aspect ... they unknowingly developed insomnia and the steps often used to ... Tune in to the show at this link: Dr. ... on August 30, and will be podcasted at this ... to DrCarolFrancisTalkRadio.com. , "Insomnia causes countless unrecognized complications. ...
(Date:8/30/2014)... In today’s world, a good night’s sleep ... and sleep apnea (a medical problem where the airway collapses ... partners of the rest they need to face their daily ... and 20 million people in the United States alone have ... treated; and of those treated, many cannot tolerate their prescribed ...
(Date:8/30/2014)... commonly used to treat gout, before and after ... complications from this type of surgery, but it ... according to a study published by JAMA ... to coincide with its presentation at the European ... cardiac surgery include postpericardiotomy syndrome (the occurrence of ...
(Date:8/30/2014)... York (PRWEB) August 30, 2014 Serving ... company in India, Profit By Outsourcing is now ... Development services. The company gives emphasize on putting forward ... complete product to clients. Their dedicated team of professionals ... ground-breaking results. They can handle even the critical issues ...
Breaking Medicine News(10 mins):Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2
... Solutions for Medical Equipment, Building Infrastructure and Automation, ... NEW YORK, March 23 Via Christi Health ... a wide range of technology and service solutions ... Christi Health System,s strategic plan.(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ...
... Siemens Financial Services, Inc. announced today that ... to El Camino Hospital in Mountain View, California. ... a variety of Siemens Medical Solutions equipment which ... hospital under construction.(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )"For more ...
... Education Virtual Lecture for Healthcare ProfessionalsVOORHEES, N.J., March ... infection (CDI) is changing rapidly and has ... and severity. Management of CDI can be challenging ... updated. In order to effectively implement key strategies ...
... WASHINGTON, March 23 March 22 was World Water ... of the 1992 United Nations Conference on Environment and ... of World Water Day this year is Transboundary Waters: ... the Poor Act of 2005 makes access to safe ...
... MBF Healthwatch survey has revealed that a disturbing number of ... they are ,too tired, or ,can,t be bothered, having a ... 22% of parents interviewed said their children skip breakfast on ... further 20% skip breakfast on one or two school days. ...
... get relief from their symptoms and the psychological distress ... , Skin experts and psychologists at The University of ... known as ,electronic Targeted Intervention for Psoriasis, or eTIPS ... better. , "Psoriasis is a skin disease that usually ...
Cached Medicine News:Health News:Via Christi Health System and Siemens Announce Technology Alliance 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 3Health News:Clostridium difficile Infection in Primary Care: Tackling a Virulent Pathogen 2Health News:USAID World Water Day Statement 2Health News:USAID World Water Day Statement 3Health News:School kids 'wagging' breakfast are missing healthy brain fuel 2Health News:Experts turn to Web to combat distressing skin disease 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: